Institute of Pharmacology, Hannover Medical School, D-30625, Hannover, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6803-6820. doi: 10.1007/s00210-024-03050-6. Epub 2024 Mar 28.
Vitamin A supplements are used by many people, and the number of newly registered dietary supplements is continuously increasing. The preparations fall under food law and are not subject to the strict controls of pharmaceuticals. Risk indications and maximum quantity recommendations, e.g., from the Bundesinstitut für Risikobewertung (BfR) and the U.S. Food and Drug Administration (FDA) are not binding, which means that overdoses and potentially serious health problems can easily occur. The hepatotoxicity and teratogenicity of vitamin A are well documented, and other negative effects of high doses of vitamin A are also being discussed. Nevertheless, preparations with exorbitantly high doses are freely available for sale and unrestricted. In this study, 75 supplements containing vitamin A available in Germany and 26 available in the USA were critically examined on the basis of various parameters such as the recommended daily dose according to the manufacturer, daily therapy costs (DTC), the presence of warnings about overdose, use during pregnancy and breastfeeding, and information on adverse effects/interactions. The aim was to gain insights into their risk potential and to examine the need for closer monitoring and stricter guidelines for these preparations. The results show some considerable country-specific differences. Overall, there are serious deficiencies in compliance with the labeling requirements for both the German and the US preparations, and the dosages are often far too high in view of the applicable expert recommendations. Overall, these deficits can pose a risk for consumers that is difficult to assess in its entirety, especially for vulnerable consumer groups. It should be noted that the US preparations perform better overall than the German preparations. This suggests better regulation of dietary supplements in the US market. Based on the available data and literature research, it is doubtful whether the intake of vitamin A-containing preparations, without a diagnosed vitamin A deficiency, has a positive health benefit. Furthermore, it should be examined whether vitamin A should continue to be offered over-the-counter as a food supplement.
维生素 A 补充剂被许多人使用,新注册的膳食补充剂数量不断增加。这些制剂属于食品法管辖范围,不受药品严格监管。例如,来自德国联邦风险评估研究所(BfR)和美国食品和药物管理局(FDA)的风险指示和最大数量建议不具有约束力,这意味着很容易出现用药过量和潜在的严重健康问题。维生素 A 的肝毒性和致畸性已有充分记录,其他高剂量维生素 A 的负面影响也在讨论中。然而,高剂量的制剂仍可自由销售且不受限制。在这项研究中,根据制造商建议的每日剂量、每日治疗费用(DTC)、是否有关于用药过量的警告、妊娠和哺乳期使用情况以及关于不良反应/相互作用的信息等各种参数,对德国和美国市场上的 75 种维生素 A 补充剂和 26 种补充剂进行了严格检查。目的是了解它们的风险潜力,并研究是否需要对这些制剂进行更密切的监测和更严格的指导方针。结果显示出一些相当大的国家特定差异。总体而言,德国和美国的制剂在标签要求的遵守方面都存在严重缺陷,而且鉴于适用的专家建议,剂量通常过高。总体而言,这些缺陷可能对消费者构成难以全面评估的风险,尤其是对弱势消费群体。值得注意的是,美国的制剂总体上比德国的制剂表现更好。这表明美国市场对膳食补充剂的监管更好。根据现有数据和文献研究,维生素 A 补充剂在没有诊断出维生素 A 缺乏症的情况下,是否对健康有积极影响值得怀疑。此外,还应研究是否应继续将维生素 A 作为食品补充剂在柜台提供。